Christopher Brynczka

Christopher Brynczka is a seasoned professional in toxicology and nonclinical development, currently serving as the Sr. Director at Biohaven since October 2023. Prior to this role, Christopher was the Director of Preclinical at CAMP4 Therapeutics, overseeing safety assessment and DMPK/bioanalytical functions for antisense oligonucleotide programs from June 2021 to October 2023. Christopher's extensive experience includes positions at Merck, where responsibilities spanned from Sr. Principal Scientist to Principal Scientist in Safety Assessment, as well as roles at Idenix Pharmaceuticals, Gradient, and Seaside Therapeutics, demonstrating a strong foundation in regulatory toxicology and product development. Academic qualifications include a PhD in Molecular and Cellular Toxicology from North Carolina State University and a BS in Animal Science from Rutgers University.